WEBULL

MacroGenics, Inc. (NASDAQ:MGNX) Looks Inexpensive After Falling 42% But Perhaps Not Attractive Enough

Simply Wall St · 04/14/2025 12:43

Unfortunately for some shareholders, the MacroGenics, Inc. (NASDAQ:MGNX) share price has dived 42% in the last thirty days, prolonging recent pain. The recent drop completes a disastrous twelve months for shareholders, who are sitting on a 92% loss during that time.

After such a large drop in price, MacroGenics may look like a strong buying opportunity at present with its price-to-sales (or "P/S") ratio of 0.5x, considering almost half of all companies in the Biotechs industry in the United States have P/S ratios greater than 8.4x and even P/S higher than 47x aren't out of the ordinary. Although, it's not wise to just take the P/S at face value as there may be an explanation why it's so limited.

Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit.

View our latest analysis for MacroGenics

ps-multiple-vs-industry
NasdaqGS:MGNX Price to Sales Ratio vs Industry April 14th 2025

What Does MacroGenics' P/S Mean For Shareholders?

With revenue growth that's inferior to most other companies of late, MacroGenics has been relatively sluggish. It seems that many are expecting the uninspiring revenue performance to persist, which has repressed the growth of the P/S ratio. If you still like the company, you'd be hoping revenue doesn't get any worse and that you could pick up some stock while it's out of favour.

Keen to find out how analysts think MacroGenics' future stacks up against the industry? In that case, our free report is a great place to start.

Is There Any Revenue Growth Forecasted For MacroGenics?

The only time you'd be truly comfortable seeing a P/S as depressed as MacroGenics' is when the company's growth is on track to lag the industry decidedly.

If we review the last year of revenue growth, the company posted a terrific increase of 155%. Pleasingly, revenue has also lifted 94% in aggregate from three years ago, thanks to the last 12 months of growth. So we can start by confirming that the company has done a great job of growing revenue over that time.

Looking ahead now, revenue is anticipated to slump, contracting by 29% per annum during the coming three years according to the six analysts following the company. Meanwhile, the broader industry is forecast to expand by 173% each year, which paints a poor picture.

With this in consideration, we find it intriguing that MacroGenics' P/S is closely matching its industry peers. However, shrinking revenues are unlikely to lead to a stable P/S over the longer term. There's potential for the P/S to fall to even lower levels if the company doesn't improve its top-line growth.

The Bottom Line On MacroGenics' P/S

Having almost fallen off a cliff, MacroGenics' share price has pulled its P/S way down as well. Typically, we'd caution against reading too much into price-to-sales ratios when settling on investment decisions, though it can reveal plenty about what other market participants think about the company.

It's clear to see that MacroGenics maintains its low P/S on the weakness of its forecast for sliding revenue, as expected. As other companies in the industry are forecasting revenue growth, MacroGenics' poor outlook justifies its low P/S ratio. Unless there's material change, it's hard to envision a situation where the stock price will rise drastically.

Don't forget that there may be other risks. For instance, we've identified 4 warning signs for MacroGenics (1 is potentially serious) you should be aware of.

If these risks are making you reconsider your opinion on MacroGenics, explore our interactive list of high quality stocks to get an idea of what else is out there.